BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29259099)

  • 1. IL-2Rβ abundance differentially tunes IL-2 signaling dynamics in CD4
    Smith GA; Taunton J; Weiss A
    Sci Signal; 2017 Dec; 10(510):. PubMed ID: 29259099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-2 responsiveness of CD4 and CD8 lymphocytes: further investigations with human IL-2Rbeta transgenic mice.
    Gesbert F; Moreau JL; Thèze J
    Int Immunol; 2005 Aug; 17(8):1093-102. PubMed ID: 16037071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late expression of granulysin by microbicidal CD4+ T cells requires PI3K- and STAT5-dependent expression of IL-2Rbeta that is defective in HIV-infected patients.
    Zheng CF; Jones GJ; Shi M; Wiseman JC; Marr KJ; Berenger BM; Huston SM; Gill MJ; Krensky AM; Kubes P; Mody CH
    J Immunol; 2008 Jun; 180(11):7221-9. PubMed ID: 18490721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT5 is critical to maintain effector CD8+ T cell responses.
    Tripathi P; Kurtulus S; Wojciechowski S; Sholl A; Hoebe K; Morris SC; Finkelman FD; Grimes HL; Hildeman DA
    J Immunol; 2010 Aug; 185(4):2116-24. PubMed ID: 20644163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2 (IL-2) Interacts With IL-2 Receptor Beta (IL-2Rβ): Its Potential to Enhance the Proliferation of CD4+ T Lymphocytes in Flounder (
    Zhou X; Xing J; Tang X; Sheng X; Chi H; Zhan W
    Front Immunol; 2020; 11():531785. PubMed ID: 33013923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Abundance and Availability of Cytokine Receptor IL-2Rβ (CD122) Constrain the Lymphopenia-Induced Homeostatic Proliferation of Naive CD4 T Cells.
    Keller HR; Kim HK; Jo Y; Gress RE; Hong C; Park JH
    J Immunol; 2020 Jun; 204(12):3227-3235. PubMed ID: 32393513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric γc cytokine receptors confer cytokine independent engraftment of human T lymphocytes.
    Hunter MR; Prosser ME; Mahadev V; Wang X; Aguilar B; Brown CE; Forman SJ; Jensen MC
    Mol Immunol; 2013 Nov; 56(1-2):1-11. PubMed ID: 23628622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-2 promotes the function of memory-like autoregulatory CD8+ T cells but suppresses their development via FoxP3+ Treg cells.
    Shameli A; Yamanouchi J; Tsai S; Yang Y; Clemente-Casares X; Moore A; Serra P; Santamaria P
    Eur J Immunol; 2013 Feb; 43(2):394-403. PubMed ID: 23180662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells.
    Burchill MA; Yang J; Vogtenhuber C; Blazar BR; Farrar MA
    J Immunol; 2007 Jan; 178(1):280-90. PubMed ID: 17182565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.
    Levin AM; Bates DL; Ring AM; Krieg C; Lin JT; Su L; Moraga I; Raeber ME; Bowman GR; Novick P; Pande VS; Fathman CG; Boyman O; Garcia KC
    Nature; 2012 Mar; 484(7395):529-33. PubMed ID: 22446627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-2 Modulates the TCR Signaling Threshold for CD8 but Not CD4 T Cell Proliferation on a Single-Cell Level.
    Au-Yeung BB; Smith GA; Mueller JL; Heyn CS; Jaszczak RG; Weiss A; Zikherman J
    J Immunol; 2017 Mar; 198(6):2445-2456. PubMed ID: 28159902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppressor of cytokine signaling 1 regulates IL-15 receptor signaling in CD8+CD44high memory T lymphocytes.
    Ilangumaran S; Ramanathan S; La Rose J; Poussier P; Rottapel R
    J Immunol; 2003 Sep; 171(5):2435-45. PubMed ID: 12928391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective expansion of genetically modified T cells using an antibody/interleukin-2 receptor chimera.
    Sogo T; Kawahara M; Tsumoto K; Kumagai I; Ueda H; Nagamune T
    J Immunol Methods; 2008 Aug; 337(1):16-23. PubMed ID: 18589435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutting Edge: Differential Fine-Tuning of IL-2- and IL-15-Dependent Functions by Targeting Their Common IL-2/15Rβ/γc Receptor.
    Meghnem D; Morisseau S; Frutoso M; Trillet K; Maillasson M; Barbieux I; Khaddage S; Leray I; Hildinger M; Quéméner A; Jacques Y; Mortier E
    J Immunol; 2017 Jun; 198(12):4563-4568. PubMed ID: 28507024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interaction of LCK and the CD4 co-receptor alters the dose response of T-cells to interleukin-7.
    Kittipatarin C; Tschammer N; Khaled AR
    Immunol Lett; 2010 Jul; 131(2):170-81. PubMed ID: 20433867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2.
    Malek TR; Yu A; Vincek V; Scibelli P; Kong L
    Immunity; 2002 Aug; 17(2):167-78. PubMed ID: 12196288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Receptor-Associated Protein Complex Assembly in Interleukin (IL)-2- and IL-15-Activated T-Cell Lines.
    Osinalde N; Sanchez-Quiles V; Akimov V; Aloria K; Arizmendi JM; Blagoev B; Kratchmarova I
    J Proteome Res; 2017 Jan; 16(1):106-121. PubMed ID: 27463037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-2 receptor gamma chain cytokines differentially regulate human CD8+CD127+ and CD8+CD127- T cell division and susceptibility to apoptosis.
    Crawley AM; Katz T; Parato K; Angel JB
    Int Immunol; 2009 Jan; 21(1):29-42. PubMed ID: 19011158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
    Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
    J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proliferation and differentiation of CD8+ T cells in the absence of IL-2/15 receptor beta-chain expression or STAT5 activation.
    Teague RM; Tempero RM; Thomas S; Murali-Krishna K; Nelson BH
    J Immunol; 2004 Sep; 173(5):3131-9. PubMed ID: 15322173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.